Automated severity scoring of atopic dermatitis patients by a deep neural network.

Sci Rep

Department of Dermatology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Korea.

Published: March 2021

Scoring atopic dermatitis (AD) severity with the Eczema Area and Severity Index (EASI) in an objective and reproducible manner is challenging. Automated measurement of erythema, papulation, excoriation, and lichenification severity using images has not yet been investigated. Our aim was to determine whether convolutional neural networks (CNNs) could assess erythema, papulation, excoriation, and lichenification severity at a level of competence comparable to dermatologists. We created a standard dataset of 8,000 clinical images showing AD. Each component of the EASI was scored from 0 to 3 by three dermatologists. We trained four CNNs (ResNet V1, ResNet V2, GoogLeNet, and VGG-Net) with the image dataset and determined which CNN was the most suitable for erythema, papulation, excoriation, and lichenification scoring. The brightness of the images in each dataset was adjusted to - 80% to + 80% of the original brightness (i.e., 9 levels by 20%) to investigate if the CNNs accurately measured scores if image brightness levels were changed. Compared to the dermatologists' scoring, accuracy rates of the CNNs were 99.17% for erythema, 93.17% for papulation, 96.00% for excoriation, and 97.17% for lichenification. CNNs trained with brightness-adjusted images achieved a high accuracy without the need to standardize camera settings. These results suggested that CNNs perform at level of competence comparable to dermatologists for scoring erythema, papulation, excoriation, and lichenification severity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961024PMC
http://dx.doi.org/10.1038/s41598-021-85489-8DOI Listing

Publication Analysis

Top Keywords

erythema papulation
16
papulation excoriation
16
excoriation lichenification
16
lichenification severity
12
scoring atopic
8
atopic dermatitis
8
level competence
8
competence comparable
8
comparable dermatologists
8
brightness levels
8

Similar Publications

Nemolizumab is an effective treatment for pruritus in atopic dermatitis, but it has a relatively high incidence of cutaneous adverse events (cAEs). To optimize the use of nemolizumab, we investigated the relationship between baseline severity in specific body areas and the frequency of cAEs. Our findings revealed that cases who discontinued treatment with nemolizumab had more severe erythema and edema/papulation on the trunk than those who continued nemolizumab.

View Article and Find Full Text PDF
Article Synopsis
  • Atopic dermatitis (AD) is a skin condition that can be difficult to treat in certain body areas; this study focused on how lebrikizumab impacts AD severity across different regions.
  • In two clinical trials, lebrikizumab was administered every two weeks, and patients showed significant improvement in the Eczema Area and Severity Index (EASI) after 16 weeks compared to those given a placebo.
  • Results indicated that lebrikizumab led to rapid improvements in AD symptoms, with significant advancements observable as early as week 2, particularly benefiting all body regions and clinical signs measured.
View Article and Find Full Text PDF
Article Synopsis
  • - Atopic dermatitis is a chronic skin condition causing eczema and itching, and Janus kinase inhibitors like upadacitinib are effective for treating moderate-to-severe cases.
  • - A study evaluated 23 Japanese patients who switched from a 15 mg to a 30 mg dose of upadacitinib after showing insufficient improvement, measuring skin severity and itching at various intervals.
  • - Results showed significant improvements in skin severity and itching at weeks 4 and 12 post-dose increase, indicating that 30 mg upadacitinib can be a viable option for patients not responding well to the lower dose.
View Article and Find Full Text PDF

Patients with eczema with a systemic metal allergy, such as nickel (Ni), cobalt (Co), chromium (Cr), and tin (Sn), should pay attention to symptomatic exacerbation by excessive metal intake in food. However, dietary intervention for systemic metal allergy can be difficult. In this study, we evaluated the effect of dietary intervention by a registered dietitian on clinical symptoms in patients with a systemic metal allergy.

View Article and Find Full Text PDF

Background: Atopic dermatitis (AD) is a chronic eczematous disease with severe pruritus. Janus kinase (JAK) inhibitors, upadacitinib, baricitinib, and abrocitinib, are systemic treatments for AD. The outcomes of switching from one JAK inhibitor to another have not been examined.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!